Dr. Gearóid Tuohy

Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).

Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced approval of CIMERLI (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications  – for… Read More »Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).

Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new preclinical data from studies evaluating gene therapies, termed… Read More »Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.

Aflibercept monotherapy or “bevacizumab first” for diabetic macular edema assessed the evidence on visual outcomes and costs to the healthcare system.

Researchers in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network has reported that the treatment of moderate vision loss due to diabetic macular edema found… Read More »Aflibercept monotherapy or “bevacizumab first” for diabetic macular edema assessed the evidence on visual outcomes and costs to the healthcare system.